Clinical Trials | December 30, 2025
Biohaven reports Phase 2 depression trial results
Despite some promising subgroup signals, the company indicated it will not pursue further psychiatric trials
Despite some promising subgroup signals, the company indicated it will not pursue further psychiatric trials
Ushio, a leader in advanced optical technologies, brings a strong track record and proprietary Photobonding technology
Shonan iPark was chosen for its globally connected life-science ecosystem, which unites pharmaceutical firms, next-generation medicine developers, AI and digital health innovators, venture capital, and academia
NUFYMCO BLA has been approved by the USFDA
Using a combination of blood and faecal samples, the service examines key biomarkers, including hereditary genetic status
The announcement came during the inauguration of the college’s Innovation & Incubation Centre and Health Club
Company acquires People Tree Hospital Yeshwanthpur for Rs. 430 crore
The update promises to revolutionize laboratory workflows by optimizing resources
GS-098, a first-in-class, humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor, is designed to rapidly block the pathogenic activity of thyroid-stimulating autoantibodies
The reform is set to modernise how medicines are developed, authorised, and made available across the EU
Subscribe To Our Newsletter & Stay Updated
